European Commission Approves Abecma, or idecabtagene vicleucel, for Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/european-commission-approves-abecman-earlier-therapy-rrmm)